Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
N/A for expanded access
Inclusion Criteria:
Exclusion Criteria:
Madison, Wisconsin 53792-4108, United States
Bordeaux, Aquitaine 33076, France
Ramat Gan, Central District 5262100, Israel
Chuo-ku, Tokyo 104-0045, Japan